NASDAQ:SMMT

Summit Therapeutics Stock News

etoro logo Buy SMMT
*Your capital is at risk
$15.07
+0.210 (+1.41%)
At Close: Jun 03, 2026
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the 43rd Annual J.P.
No one knows for sure what the new year will hold for the market. However, some stocks' chances for success look particularly good.

Best-Performing Stocks Of 2024

11:46pm, Thursday, 02'nd Jan 2025
Best-Performing Stocks Of 2024

3 Stocks That Could Be Monster Winners in 2025

06:47am, Sunday, 29'th Dec 2024
What do many kids like most about the coming of a new year? The fireworks.

Where Will Summit Therapeutics Be in 5 Years?

06:30am, Friday, 20'th Dec 2024
Summit Therapeutics (SMMT 8.36%) has risen in prominence in the past two years thanks to a promising pipeline candidate, ivonescimab, a potential cancer treatment. The company's shares are up by 340%
A five-bagger in only five years? Any investor would love to buy such a stock.
Investing in biotech stocks usually isn't for the faint of heart. These stocks tend to be highly volatile because of the inherent risks of developing new drugs.
It's been a good year for the stock market as a whole and a tremendous year for a couple of drugmaker start-ups. Shares of Viking Therapeutics (VKTX -1.75%) and Summit Therapeutics (SMMT -0.22%) more
Normally, you might expect to achieve significant gains from stocks if you invest in them for years, perhaps decades. But given how hot the stock market has been this year, some stocks have produced l
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of
SMMT stock rose after analysts at Jefferies initiated coverage on it, citing optimism about the company's lead pipeline drug.
Summit Therapeutics (SMMT 5.82%) stock got a real shot in the arm Friday with the initiation of coverage by a veteran financial services company. On news that Jefferies is now tracking the stock, inve
Summit Therapeutics reached a milestone in its Phase III trial for ivonescimab, aiming to treat second-line EGFR mutated advanced NSCLC.  The FDA has fast tracked the HARMONi trial. Positive Phase II
Do you ever wonder what America's wealthiest stock traders are buying and selling? Thanks to the Securities and Exchange Commission, you don't have to.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE